Glioblastoma (GBM) is a life-threading disease, striking all corners of society regardless of gender, age, background, or income level. While there have been improvements in surgical procedures and multimodal therapy to treat brain cancer cases, the challenge persists – its difficult diagnosis, expensive treatments, and relentless nature of the fight against glioblastoma (GBM). It can be a heartbreaking experience for families. GBM remains one of medicine’s most formidable enemies due to its resistance to treatment and fierce grip on those affected.
Dr. Rashida Karmali, CEO of Tactical Therapeutics, and her team have achieved a significant milestone – high-profile organizations have recognized their drug Carboxyamidotriazole Orotate (CTO) after the successful completion of its phase 1 trial at Memorial Kettering Hospital.
CTO is an innovative treatment for brain cancer patients suffering from either Glioblastoma recurrence (GBM) or newly diagnosed cases nGBM). This excellent news marks a significant advancement in healthcare innovation as we further our understanding of treating life-threatening conditions like GBM.
Tactical Therapeutics, Inc., a clinical-stage biopharma company, is thrilled to announce its selection for the upcoming MedInvest Oncology Investor Conference on December 14th and 15th in New York City.
The CEO of Tactical, Rashida Karmali, Ph.D. exclaimed that they warmly welcome this opportunity to interact with some of the leading figures within oncology, such as investors who are dedicated to improving patient care and quality of life across difficult-to-treat solid cancers – including Glioblastoma (GBM). This brain tumor has taken away countless lives; most notably, Senator Ted Kennedy, Beau Biden, and John McCain succumbed due to GBM being untreatable even today.
Recent reports highlight a heartbreaking correlation between military service and the development of Glioblastoma Multiforme (GBM) – an aggressive brain cancer affecting Vietnam, Iraq, and Afghanistan War veterans exposed to Burn Pits. This Orphan Disease typically has median overall survival rates ranging from 12-20 months for newly diagnosed cases treated with surgery, radiotherapy, and temozolomide chemotherapy; however, recurrence is commonplace within one year, reducing this rate to just ten months in many instances.
Tactical’s revolutionary drug, Carboxyamidotriazole Orotate (CTO), has been proven to dramatically improve Overall Survival time for those with nGBM from 10 months to 28+ months. The two patients who have remained recurrence-free over five years are even more impressive – showing this groundbreaking medicine’s immense potential! Published in J Clin Oncology (2018) 36:1702–709, these results prove that CTO may provide a compelling new way of treating aggressive forms of cancer.
CTO is an exciting breakthrough in the fight against cancer. This drug-patented inhibitor targets genes related to oncogenic pathways and calcium channels, providing promising results at clinically relevant levels by inhibiting some mRNA associated with tumor-causing genes while promoting suppressors. With its robust IP portfolio – featuring 8 US and 75 International patents lasting until 2040 – As a game-changing treatment option, CTO has the potential to revolutionize how we manage and treat this relentless disease.
Dr. Antonio Omuro, A respected Neuroscientist, a Fellow of the eminent American Academy of Neurology, and a renowned glioblastoma specialist, is thrilled with the promising results seen in malignant glioma patients when using CTO as a treatment option. His confidence has driven him to call for more funding for further research trials like Phase 2 on this powerful drug which could result in an FDA approval that would genuinely make a difference in people’s lives affected by these devastating diseases.
Treatment of glioblastoma (GBM) is particularly challenging, and radiographic responses are rarely seen in GBM trials. Promising results were observed for these difficult-to-treat patients – 1 complete response and six partial responders from 27 recurrent cases with previous exposure to bevacizumab.
Outstanding survival rates have also been recorded: 62% 2-year rate, 93%-1 year rate, and even two 5-year recurrence-free survivors! CTO was found safe and crossed the blood-brain barrier, which allowed it to reach high concentrations into tumors without affecting normal tissues – a breakthrough success story against one of the most challenging cancers.
Dr. Rashida Karmali is leading the charge against brain cancer with her company, Tactical Therapeutics. Tactical Therapeutics is at the forefront of developing new treatments for brain cancer patients. With cutting-edge technology and a team of passionate experts, the company is leading the fight against this devastating disease.
For more information about Tactical Therapeutics and its groundbreaking work, please visit https://www.tacticaltherapeutics.com/ or at https://pitchbook.com/profiles/company/123576-67 today.
Sponsored Post
